<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988685</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00615</org_study_id>
    <nct_id>NCT04988685</nct_id>
  </id_info>
  <brief_title>SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters</brief_title>
  <acronym>SIROOP</acronym>
  <official_title>SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline,&#xD;
      clinical and procedural characteristics of patients who have undergone PCI and are treated&#xD;
      with either currently available sirolimus or paclitaxel coated DCBs (see Table 1),&#xD;
      irrespective of clinical presentation as well as to prospectively collect data about their&#xD;
      clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of&#xD;
      current DCBs in different clinical settings and coronary artery lesions on cardiovascular&#xD;
      outcomes will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives in detail:&#xD;
&#xD;
        -  To evaluate procedural success, efficacy, performance and clinical outcomes among&#xD;
           various patient cohorts, who undergo PCI using currently available DCBs:&#xD;
&#xD;
             1. Periprocedural outcomes/complications, which will be analyzed, include: final&#xD;
                result (e.g. residual stenosis, TIMI flow), dissections, perforations, prevalence&#xD;
                of thrombus (assessed by angiography and intravascular imaging)&#xD;
&#xD;
             2. Short and long-term clinical outcomes of interest comprise among others: new MI,&#xD;
                unstable angina (UA), target lesion failure, target vessel revascularization,&#xD;
                target lesion failure/ revascularization, repeat hospitalization, new/worsening&#xD;
                heart failure, cardiogenic shock, stroke, bleedings, cardiovascular death and&#xD;
                all-cause death.&#xD;
&#xD;
        -  To describe procedural and clinical performance of various DCB, either alone or in&#xD;
           combination with other stent and coronary scaffold devices&#xD;
&#xD;
        -  To identify optimal strategies for lesion preparation in cases treated with DCB&#xD;
&#xD;
        -  To identify possible predictors for TLR after treatment with DCB&#xD;
&#xD;
        -  To describe early and late angiographic and OCT-findings among coronary artery disease&#xD;
           (CAD) patients treated with DCB and/or various metallic stent and scaffold devices&#xD;
&#xD;
        -  To evaluate the impact of different antithrombotic regimens on patient's clinical&#xD;
           outcomes&#xD;
&#xD;
        -  To study procedural and clinical outcomes among CAD patients requiring hemodynamic&#xD;
           support using mechanical devices.&#xD;
&#xD;
        -  To describe economic implications (cost-effectiveness) of various interventional&#xD;
           treatments for CAD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Target lesion failure (TLF) and target lesion revascularization (TLR) rate</measure>
    <time_frame>at 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combination of major adverse cardiac and cerebrovascular events (MACCE) (including new MI, TLR or cardiovascular death)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New MI (NSTEMI / STEMI)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIA or stroke</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute vessel closure</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis or ISR</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia driven TLR</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All myocardial infarction and TV-MI</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for recurrent angina</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for HF</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rehospitalization for HF, resuscitated cardiac arrest or implantable cardioverter- defibrillator (ICD) implantation</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events (access site or non-access site related) according to the BARC classification</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular complications (according to VARC criteria)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiogenic shock</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure/ contrast-induced nephropathy (CIN)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New ventricular arrhythmias</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse limb events (MALE)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) class</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina according to Canadian Cardiovascular Society (CCS) Score</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success (final diameter stenosis &lt; 30% without flow-limiting dissections)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural complications (e.g. coronary perforations, no-reflow)</measure>
    <time_frame>at 180 days, 1, 2 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Restenosis</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <condition>Coronary Artery Calcification</condition>
  <condition>Stable Chronic Angina</condition>
  <condition>Angina Pectoris</condition>
  <condition>Angina, Stable</condition>
  <condition>Angina, Unstable</condition>
  <condition>Stent Thrombosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>The project ÃÅs main goal is to collect baseline, clinical and procedural data as well as to assess angiographic and clinical outcomes of CAD patients treated with contemporary DCBs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus Eluting Balloon</intervention_name>
    <description>PTCA with either a Sirolimus eluting balloon or Paclitaxel eluting balloon</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Paclitaxel Eluting Balloon</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This registry will recruit consecutive patients treated with either DCB alone or a hybrid&#xD;
        strategy (metallic stent plus DCB). Ideally any patient treated with a DCB will be included&#xD;
        in the present registry, either presenting with a de-novo coronary lesion (either elective&#xD;
        or urgent procedure), with a ST or ISR.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject &gt;18 years of age&#xD;
&#xD;
          -  Patients with significant acute or chronic coronary de-novo lesions or ISR lesions&#xD;
             requiring treatment using PCI&#xD;
&#xD;
          -  Treatment with at least one DCB (device choice at the operator's discretion) In case&#xD;
             of a patient with lesions treated at different procedural time, lesions will be&#xD;
             separately collected and documented&#xD;
&#xD;
          -  Subjects must be willing to sign a patient informed consent (PIC) or must have signed&#xD;
             the General Consent (GK).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is &lt;18 years of age&#xD;
&#xD;
          -  Patient unwilling or unable to provide informed consent&#xD;
&#xD;
          -  pregnancy and lactation&#xD;
&#xD;
          -  Indication for surgical revascularization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florim Cuculi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luzerner Kantonsspital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florim Cuculi, MD</last_name>
    <phone>+41412052134</phone>
    <email>florim.cuculi@luks.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthias Bossard, MD</last_name>
    <phone>+41412051477</phone>
    <email>matthias.bossard@luks.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Luzerner Heart Centre</name>
      <address>
        <city>Lucerne</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florim Cuculi, MD</last_name>
      <phone>+41412052134</phone>
      <email>florim.cuculi@luks.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Luzerner Kantonsspital</investigator_affiliation>
    <investigator_full_name>Matthias Bossard</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

